Bon Announces Breakthrough Order for $16 Million Gut-Health Products
Bon Natural Life (Nasdaq: BON) has secured a significant $16 million non-exclusive distribution agreement with Beijing Huahai Keyuan Technology for its natural prebiotic product series in China. The 24-month agreement focuses on marketing and distributing BON's advanced gut health products featuring a "Prebiotic + Postbiotic" complex with super prebiotic stachyose as the flagship ingredient.
The partnership leverages Huahai Keyuan's strong market presence and commercialization expertise in China's wellness sector. BON's innovative formulation aims to provide rapid and sustained support for gut microbiota, potentially redefining the gut health market while driving growth and shareholder value.
Bon Natural Life (Nasdaq: BON) ha siglato un importante accordo di distribuzione non esclusivo da 16 milioni di dollari con Beijing Huahai Keyuan Technology per la sua linea di prodotti prebiotici naturali in Cina. Il contratto, della durata di 24 mesi, si concentra sulla commercializzazione e distribuzione dei prodotti avanzati per la salute intestinale di BON, caratterizzati da un complesso "Prebiotico + Postbiotico" con stachiosio super prebiotico come ingrediente principale.
La collaborazione sfrutta la forte presenza di mercato e l'expertise commerciale di Huahai Keyuan nel settore del benessere cinese. La formulazione innovativa di BON mira a fornire un supporto rapido e duraturo per il microbiota intestinale, potenzialmente ridefinendo il mercato della salute intestinale e favorendo la crescita e il valore per gli azionisti.
Bon Natural Life (Nasdaq: BON) ha asegurado un importante acuerdo de distribuci贸n no exclusivo por 16 millones de d贸lares con Beijing Huahai Keyuan Technology para su serie de productos prebi贸ticos naturales en China. El acuerdo de 24 meses se centra en la comercializaci贸n y distribuci贸n de los avanzados productos para la salud intestinal de BON, que cuentan con un complejo "Prebi贸tico + Postbi贸tico" con estaciosa super prebi贸tica como ingrediente principal.
La asociaci贸n aprovecha la fuerte presencia en el mercado y la experiencia comercial de Huahai Keyuan en el sector del bienestar en China. La formulaci贸n innovadora de BON busca ofrecer un apoyo r谩pido y sostenido para la microbiota intestinal, con el potencial de redefinir el mercado de la salud intestinal y fomentar el crecimiento y el valor para los accionistas.
Bon Natural Life (雮橃姢雼�: BON)鞚� 欷戧淡鞐愳劀 鞛愳棸 頂勲Μ氚旍澊鞓ろ嫳 鞝滍拡 鞁滊Μ歃堧ゼ 鞙勴暅 1,600毵� 雼煬 攴滊鞚� 牍勲弲鞝� 鞙犿喌 瓿勳暯鞚� 氩犾澊歆� 頇旐暣鞚� 旎れ渼鞎� 韰岉伂雴�搿滌鞕� 觳搓舶頄堨姷雼堧嫟. 鞚� 24臧滌洈 瓿勳暯鞚� BON鞚� 觳嫧 鞛� 瓯搓皶 鞝滍拡鞚� 毵堨紑韺呿晿瓿� 鞙犿喌頃橂姅 雿� 欷戩爯鞚� 霊愲┌, 鞀堩嵓 頂勲Μ氚旍澊鞓ろ嫳 鞀ろ儉韨れ槫鞀るゼ 欤检劚攵勳溂搿� 頃橂姅 "頂勲Μ氚旍澊鞓ろ嫳 + 韽姢韸鸽皵鞚挫槫韹�" 氤淀暕觳措ゼ 韸轨鞙茧 頃╇媹雼�.
鞚措矆 韺岉姼雱堨嫮鞚� 欷戧淡 鞗半媹鞀� 攵勳暭鞐愳劀 頇旐暣鞚� 旎れ渼鞎堨潣 臧曤牓頃� 鞁滌灔 鞛呾鞕� 靸侅梾頇� 鞝勲靹膘潉 頇滌毄頃╇媹雼�. BON鞚� 順侅嫚鞝侅澑 鞝滍槙鞚� 鞛ル偞 氙胳儩氍缄蛋鞐� 牍犽ゴ瓿� 歆�靻嶌爜鞚� 歆�鞗愳潉 鞝滉车頃橃棳 鞛� 瓯搓皶 鞁滌灔鞚� 鞛爼鞚橅晿瓿� 靹膘灔瓿� 欤检＜ 臧�旃橂ゼ 齑夓頃� 臧�電レ劚鞚� 鞛堨姷雼堧嫟.
Bon Natural Life (Nasdaq : BON) a conclu un accord de distribution non exclusif important de 16 millions de dollars avec Beijing Huahai Keyuan Technology pour sa gamme de produits pr茅biotiques naturels en Chine. Cet accord de 24 mois se concentre sur la commercialisation et la distribution des produits avanc茅s pour la sant茅 intestinale de BON, mettant en avant un complexe 芦 Pr茅biotique + Postbiotique 禄 avec la stachyose super pr茅biotique comme ingr茅dient phare.
Ce partenariat exploite la forte pr茅sence sur le march茅 et l'expertise commerciale de Huahai Keyuan dans le secteur du bien-锚tre en Chine. La formulation innovante de BON vise 脿 offrir un soutien rapide et durable au microbiote intestinal, avec le potentiel de red茅finir le march茅 de la sant茅 intestinale tout en stimulant la croissance et la valeur pour les actionnaires.
Bon Natural Life (Nasdaq: BON) hat eine bedeutende nicht-exklusive Vertriebsvereinbarung 眉ber 16 Millionen US-Dollar mit Beijing Huahai Keyuan Technology f眉r seine nat眉rliche Pr盲biotika-Produktserie in China abgeschlossen. Die 24-monatige Vereinbarung konzentriert sich auf das Marketing und den Vertrieb von BONs fortschrittlichen Darmgesundheitsprodukten mit einem "Pr盲biotikum + Postbiotikum"-Komplex, bei dem Super-Pr盲biotikum Stachyose die Hauptzutat ist.
Die Partnerschaft nutzt die starke Marktpr盲senz und Vertriebsexpertise von Huahai Keyuan im chinesischen Wellness-Sektor. BONs innovative Formulierung zielt darauf ab, eine schnelle und nachhaltige Unterst眉tzung der Darmmikrobiota zu bieten, was den Markt f眉r Darmgesundheit potenziell neu definieren und Wachstum sowie Aktion盲rswert f枚rdern k枚nnte.
- Secured $16 million distribution agreement for gut health products
- 24-month partnership with established Chinese wellness company
- Entry into China's rapidly growing gut health market
- Innovative product featuring advanced Prebiotic + Postbiotic complex
- Non-exclusive distribution agreement limits market protection
- Revenue generation dependent on partner's sales performance
Insights
Bon secures $16M gut-health distribution deal in China, potentially boosting revenue significantly over next 24 months.
This $16 million distribution agreement represents a notable commercial breakthrough for BON, potentially delivering substantial revenue over the next 24 months. The non-exclusive nature of the deal preserves BON's ability to pursue additional distribution partnerships, maximizing market penetration potential.
Looking at the structure, this agreement creates a clear commercialization pathway for BON's prebiotic products in the massive Chinese health supplements market, which has been experiencing double-digit growth rates. The partnership leverages Huahai Keyuan's established distribution network and marketing expertise, potentially reducing BON's go-to-market costs while accelerating market entry.
What's particularly significant is how this deal aligns with BON's specialized focus on natural bio-ingredients and prebiotic formulations. The company's emphasis on their "Prebiotic + Postbiotic" complex suggests they've developed differentiated intellectual property in the rapidly expanding gut health sector, which has seen growing scientific validation and consumer adoption.
While the press release doesn't specify exact revenue recognition timing or margin structure, the $16 million contract value over 24 months could represent meaningful top-line growth for a company of BON's size. Management's repeated emphasis on "substantial growth opportunities" and "strong commercial outcomes" signals confidence in the partnership's potential to drive material financial performance improvements.
BON believes their latest natural prebiotic product series marks a significant step forward in gut health, featuring a cutting-edge "Prebiotic + Postbiotic" complex centered on its flagship active ingredient: super prebiotic stachyose. This advanced formulation intends to deliver rapid, robust, and sustained support for gut microbiota, promoting a multi-fold increase in beneficial probiotic populations within a short period while maintaining excellent stability.
With its efficacy and market potential, this solution is poised to help redefine the future of gut health.
Yongwei Hu , Chairman and CEO of BON, stated "As a global leader in 'prebiotic + postbiotic' health solutions, we are thrilled to launch a premium gut health product with robust and sustained bioactive properties, and to establish a distribution partnership with Huahai Keyuan鈥攁n organization well-regarded for its strong market presence and commercialization expertise." Mr. Hu added "Huahai Keyuan brings deep experience in introducing innovative health products to the Chinese market, with a proven track record in market expansion and brand development."
Mr. Hu further stated, "At BON, we believe this strategic collaboration will accelerate our entry into
Additionally, Mr. Hu also stated: "This partnership with Huahai Keyuan marks a transformative step in scaling our integrated gut health solutions. We anticipate strong commercial outcomes that will drive both top-line growth and long-term shareholder value."
About Bon Natural Life Limited ("BON")
BON is a
For more information, please contact:
Cindy Liu | IR
Email: [email protected]
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
View original content:
SOURCE Bon Natural Life Limited
FAQ
What is the value of BON's new distribution agreement with Huahai Keyuan?
What products will Huahai Keyuan distribute for BON?
How long is BON's distribution agreement with Huahai Keyuan?
What is unique about BON's new gut health product?
Who is Huahai Keyuan and why did BON choose them as a distributor?
